These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 34232923)
1. Effective Treatment of Chronic Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir in 2 Teenagers With HIV Coinfection: A Brief Report. Pokorska-Śpiewak M; Dobrzeniecka A; Ołdakowska A; Marczyńska M Pediatr Infect Dis J; 2021 Dec; 40(12):1087-1089. PubMed ID: 34232923 [TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z; Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043 [TBL] [Abstract][Full Text] [Related]
3. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). Rosenthal E; Fougerou-Leurent C; Renault A; Carrieri MP; Marcellin F; Garraffo R; Teicher E; Aumaitre H; Lacombe K; Bailly F; Billaud E; Chevaliez S; Dominguez S; Valantin MA; Reynes J; Naqvi A; Cotte L; Metivier S; Leroy V; Dupon M; Allegre T; De Truchis P; Jeantils V; Chas J; Salmon-Ceron D; Morlat P; Neau D; Perré P; Piroth L; Pol S; Bourlière M; Pageaux GP; Alric L; Zucman D; Girard PM; Poizot-Martin I; Yazdanpanah Y; Raffi F; Pabic EL; Tual C; Pailhé A; Amri I; Bellissant E; Molina JM; HIV Med; 2018 Mar; 19(3):227-237. PubMed ID: 29214737 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection. Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Tao T; Jiang X; Chen Y; Song Y Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient. Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007 [TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776 [TBL] [Abstract][Full Text] [Related]
10. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Walsh CE; Workowski K; Terrault NA; Sax PE; Cohen A; Bowlus CL; Kim AY; Hyland RH; Han B; Wang J; Stamm LM; Brainard DM; McHutchison JG; von Drygalski A; Rhame F; Fried MW; Kouides P; Balba G; Reddy KR Haemophilia; 2017 Mar; 23(2):198-206. PubMed ID: 28124511 [TBL] [Abstract][Full Text] [Related]
11. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893 [TBL] [Abstract][Full Text] [Related]
12. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754 [TBL] [Abstract][Full Text] [Related]
13. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470 [TBL] [Abstract][Full Text] [Related]
14. Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis. Smith SK; Rosenthal P J Pediatr Gastroenterol Nutr; 2016 Nov; 63(5):516-517. PubMed ID: 27243422 [TBL] [Abstract][Full Text] [Related]
15. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679 [TBL] [Abstract][Full Text] [Related]
16. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757 [TBL] [Abstract][Full Text] [Related]
17. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N; Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734 [TBL] [Abstract][Full Text] [Related]
18. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Keating GM Drugs; 2015 Apr; 75(6):675-85. PubMed ID: 25837989 [TBL] [Abstract][Full Text] [Related]
19. Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. Jensen CM; Holle LM Pharmacotherapy; 2016 May; 36(5):562-74. PubMed ID: 27027412 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]